-
1Academic Journal
المؤلفون: Andrey V. Orekhva, E. A. Shlyakhtunov, V. M. Semenov, I. V. Zhiltsov, A. V. Erushevich, G. M. Shappo, Ya. N. Lyakh, Alina V. Orekhva, Андрей В. Орехва, Е. А. Шляхтунов, В. М. Семенов, И. В. Жильцов, А. В. Ерушевич, Г. М. Шаппо, Я. Н. Лях, Алина В. Орехва
المساهمون: The work was carried out in accordance with the scientific research plan of the Vitebsk State Medical University. The authors did not receive financial support from drug manufacturers., Работа выполнялась в соответствии с планом научных исследований УО «Витебский государственный медицинский университет». Финансовой поддержки со стороны компаний-производителей лекарственных препаратов авторы не получали.
المصدر: Surgery and Oncology; Том 13, № 4 (2023); 17-37 ; Хирургия и онкология; Том 13, № 4 (2023); 17-37 ; 2949-5857
مصطلحات موضوعية: колоректальный рак, survivin, minimal residual disease, circulating tumor cells, colorectal cancer, сурвивин, минимальная остаточная болезнь, циркулирующие опухолевые клетки
وصف الملف: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/654/443; Bettegowda C., Sausen M., Leary R.J. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6(224):224ra24. DOI:10.1126/scitranslmed.3007094; Tie J., Wang Y., Tomasetti C. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8(346):346ra92. DOI:10.1126/scitranslmed.aaf6219; Tarazona N., Gimeno-Valiente F., Gambardella V. et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol 2019;30(11):1804–12. DOI:10.1093/annonc/mdz390; Tan Y., Wu H. The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis. Curr Probl Cancer 2018;42(1):95–106. DOI:10.1016/j.currproblcancer.2017.11.002; Alberter B., Klein Ch.A., Polzer B. Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. Expert Rev Mol Diagn 2016:16(1):25–38. DOI:10.1586/14737159.2016.1121099; Marcuello M., Vymetalkova V., Neves R.P. et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspects Med 2019;69:107–22. DOI:10.1016/j.mam.2019.06.002; Andersen M.H., Svane I.M., Becker J.C. et al. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007;13(20):5991–4. DOI:10.1158/1078-0432.CCR-07-0686; Shintani M., Sangawa A., Yamao N. et al. Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp Pathol 2013;6(12):2919–27.; Choi J., Chang H. The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res 2012;32(2):559–64.; Miura K., Fujibuchi W., Ishida K. et al. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today 2011;41(2):175–82. DOI:10.1007/s00595-010-4390-1; Qi G., Tuncel H., Aoki E. et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep 2009;22(3):557–62. DOI:10.3892/or_00000471; Okada E., Murai Y., Matsui K. et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001;163(1):109–16. DOI:10.1016/s0304-3835(00)00677-7; Jakubowska K., Pryczynicz A., Dymicka-Piekarska V. et al. Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients. Oncol Lett 2016;12(5):3591–97. DOI:10.3892/ol.2016.5075; Devetzi M., Kosmidou V., Vlassi M. et al. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. Sci Rep 2016;6:36532. DOI:10.1038/srep36532; Kim J., Ahn S., Kim K. et al. Prognostic significance of survivin expression and combined analysis with cancer stem cell and epithelial-mesenchymal transition-related markers in patients with rectal cancer undergoing preoperative chemoradiotherapy. Anticancer Res 2018;38(12):6881–9. DOI:10.21873/anticanres.13064л; Krieg A., Werner T.A., Verde P.E. et al. Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS One 2013;8(6):e65338. DOI:10.1371/journal.pone.0065338; Huang Y.J., Qi W.X., He A.N. et al. The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis. Jpn J Clin Oncol 2013;43(10):988–95. DOI:10.1093/jjco/hyt103; https://www.onco-surgery.info/jour/article/view/654